Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer

Abstract Antiangiogenic and antilymphangiogenic gene therapy with soluble vascular endothelial growth factor receptor-2 (VEGFR-2) and soluble VEGFR-3 in combination with chemotherapy is a potential new treatment for ovarian carcinoma. We evaluated the safety, toxicology, and biodistribution of intra...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Human gene therapy. Clinical development 2013-03, Vol.24 (1), p.29-37
Hauptverfasser:	Tuppurainen, Laura, Sallinen, Hanna, Kokki, Emmi, Koponen, Jonna, Anttila, Maarit, Pulkkinen, Kati, Heikura, Tommi, Toivanen, Pyry, Hämäläinen, Kirsi, Kosma, Veli-Matti, Heinonen, Seppo, Alitalo, Kari, Ylä-Herttuala, Seppo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae - genetics Animals Antineoplastic Agents - therapeutic use Blood Chemical Analysis Drug Evaluation, Preclinical Female Genetic Therapy Genetic Vectors - genetics Genetic Vectors - metabolism Humans Liver - pathology Lung - pathology Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Rats Tissue Distribution Vascular Endothelial Growth Factor Receptor-2 - blood Vascular Endothelial Growth Factor Receptor-2 - genetics Vascular Endothelial Growth Factor Receptor-2 - metabolism Vascular Endothelial Growth Factor Receptor-3 - blood Vascular Endothelial Growth Factor Receptor-3 - genetics Vascular Endothelial Growth Factor Receptor-3 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!